Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Pfizer offers breast cancer drug for free following NICE rejection

May 5, 2017
Medical Communications, Sales and Marketing NICE, Pfizer

Following NICE’s decision rejecting Pfizer’s breast cancer therapy Ibrance (palbociclib) for use on the NHS, the manufacturer has announced that …

News

NICE recommends Janssen’s first-of-its-kind Crohn’s drug Stelara

May 3, 2017
Research and Development, Sales and Marketing Crohn’s disease, Janssen, NICE, Stelara, crohn's disease

Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely …

News
pills_spill

Cancer Drug Fund roundly criticised as ‘wastage of resources’

April 28, 2017
Medical Communications Cancer Drug Fund, Conservative, NHS, NICE, UK

The Cancer Drug Fund (CDF), which has now been absorbed into NICE, previous methods of funding have been fiercely criticised …

News
ema_building_face_web

EU recommendation for Sanofi and Regeneron’s arthritis treatment

April 24, 2017
Sales and Marketing Kevzara, NICE, sarilumab

Sanofi and Regeneron are celebrating the news that their treatment Kevzara (sarilumab) has received a positive opinion from the EMA’s …

News

England “really is not a good place” to get cancer, BMS UK General Manager says

April 24, 2017
Medical Communications, Research and Development, Sales and Marketing BMS, NICE, opdivo

Bristol-Myers Squibb’s UK General Manager Ben Hickey has slammed NICE over its assessment criteria and process in recommending access to …

News
opdivo_1_1

NICE turns down BMS’ Opdivo for head and neck cancer

April 11, 2017
Manufacturing and Production, Sales and Marketing BMS, NICE, opdivo

Bad news for Bristol-Myers Squibb as NICE chooses not to recommend its immunotherapy drug Opdivo (nivolumab) for use in head …

News
shire_image_4

NICE turns down Shire’s pancreatic cancer treatment

April 4, 2017
Manufacturing and Production, Sales and Marketing NICE, Pancreatic cancer, Shire

NICE has announced its intention not to recommend the NHS use of Shire’s Onivyde (pegylated liposomal irinotecan) for the treatment …

News
paul-catchpole

Insider Interview: ABPI’s Paul Catchpole discusses NICE’s new fast-track appraisal system

March 30, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, Insider Interview, NICE, Paul Catchpole, fast track

Paul Catchpole, Value and Access Director at the Association of the British Pharmaceutical Industry (ABPI), gives his thoughts on the …

Feature
nice_reception_small_size

NICE drug expense limit of £20 million could cause treatment delays

March 16, 2017
Medical Communications, Sales and Marketing NHS England, NICE, fast-track appraisal process, rare disease

NICE has released its decision on the fast-track approval process and other changes that will be brought through at the …

News
amgen_hq

FDA and NICE approve of first new hyperparathyroidism drug in 12 years

March 8, 2017
Research and Development, Sales and Marketing FDA, NICE, Parsabiv, hyperparathyroidism

The FDA has given the go-ahead for Amgen’s hyperparathyroidism (HPT) therapy Parsabiv (etelcalcetide), marking the first new treatment for patients …

News

Price cuts bring 14 Cancer Drugs Fund treatments into routine NHS use

March 3, 2017
Medical Communications, Sales and Marketing CDF, NICE

NICE has revealed that it has reached the halfway point in its review of the old Cancer Drugs Fund (CDF) …

News
keytruda1

NICE knocks back MSD’s Keytruda for lung cancer indication

February 28, 2017
Research and Development, Sales and Marketing MSD, NICE, NSCLC, keytruda

MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by the National Institute of Health and Care Excellence (NICE) for …

News

NICE provisionally rejects Ipsen’s kidney cancer drug Cabometyx

February 21, 2017
Manufacturing and Production, Sales and Marketing Cometriq, NICE, ipsen

NICE has announced draft guidance for Ipsen’s cancer drug Cabometyx (cabozantinib), revealing it does not recommend the drug for use on …

News

NICE turns down AZ’s chronic obstructive pulmonary disease drug

February 13, 2017
Sales and Marketing AstraZeneca, Daxas, NICE, chronic obstructive pulmonary disease

AstraZeneca’s Daxas (roflumilast) has been knocked back in draft guidance by the National Institute for Health and Care Excellence (NICE), …

News
alexion

Alexion hits out at NICE ruling on Strensiq

February 8, 2017
Research and Development, Sales and Marketing Alexion, NICE, Strensiq

NICE has again drawn the ire of a company over its recommendation of its drug, this time round it’s Alexion …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026